{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:33:18Z","timestamp":1788305598933,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.athoracsur.2019.10.091","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:43:29Z","timestamp":1577144609000},"page":"582-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve\u2013Induced Thrombin Generation"],"prefix":"10.1016","volume":"110","author":[{"given":"Iqbal H.","family":"Jaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2019.10.091_bib1","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib6","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib9","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMe1310399","article-title":"Dabigatran and mechanical heart valves \u2014 not as easy as we hoped","volume":"369","author":"Hylek","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib10","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib11","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib12","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"Dangas","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct factor Xa inhibitor--after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116835","article-title":"Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between APTT, anti-factor Xa and thrombin generation assays","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In\u00a0vitro and in\u00a0vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor","volume":"31","author":"Wong","year":"2011","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619847524","article-title":"Factor Xa inhibitory profile of apixaban, betrixaban, edoxaban, and rivaroxaban does not fully reflect their biologic spectrum","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib21","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jth.13801","article-title":"Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study","volume":"15","author":"Kreutz","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1160\/TH14-10-0877","article-title":"Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban","volume":"114","author":"Jourdi","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","article-title":"Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model","volume":"45","author":"Greiten","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","article-title":"Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model","volume":"37","author":"Lester","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/ATVBAHA.117.309223","article-title":"Anticoagulation for\u00a0mechanical heart valves: Will oral factor Xa inhibitors be\u00a0effective?","volume":"37","author":"Chan","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib26","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","article-title":"Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves","volume":"141","author":"McKellar","year":"2011","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2019.10.091_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497519319162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497519319162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T04:04:18Z","timestamp":1757736258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497519319162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0003497519319162"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2019.10.091","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve\u2013Induced Thrombin Generation","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2019.10.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The Society of Thoracic Surgeons Published by Elsevier","name":"copyright","label":"Copyright"}]}}